AbbVie Acquires Mavupharma for its STING (STimulator of INterferon Genes) Modulators to Treat Cancer

 AbbVie Acquires Mavupharma for its STING (STimulator of INterferon Genes) Modulators to Treat Cancer

AbbVie Acquires Mavupharma for its STING (STimulator of INterferon Genes) Modulators to Treat Cancer

Shots:

  • AbbVie has acquired Mavupharma to develop STING modulators and to advance Mavupharma’s lead candidate MAVU-104 towards clinical study
  • The focus of the acquisition is to bolster AbbVie’s early-stage oncology portfolio with the addition of Mavupharma’s platform which involves the development of transformative therapies for cancer patients
  • MAVU-104 is an orally administered ENPP1 inhibitor allowing highly controlled enhancement of STING signaling in tumors without the need for injections

Click here to read full press release/ article | Ref: AbbVie | Image: Mavupharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post